16499-65-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-7-(trifluoromethyl)quinazoline is used as a pharmaceutical intermediate for the synthesis of kinase inhibitors. These inhibitors are designed to block specific enzymes involved in the progression of cancer and inflammatory diseases, offering a targeted approach to treatment.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-Chloro-7-(trifluoromethyl)quinazoline serves as a key compound in the development and optimization of new drug candidates. Its unique structure and properties make it a valuable asset in the design of novel therapeutic agents with improved efficacy and safety profiles.

InChI:InChI=1/C9H4ClF3N2/c10-8-6-2-1-5(9(11,12)13)3-7(6)14-4-15-8/h1-4H

Upstream product

• 16499-58-4 4-hydroxy-7-trifluoromethylquinazoline 
• 402-13-1 2-amino-4-trifluoromethylbenzoic acid 
• 16499-58-4 7-(trifluoromethyl)quinazolin-4(3H)-one 

Downstream Products

• 129190-29-0 2,6-bis(diethylaminomethyl)-4-(7'-trifluoromethylquinazolin-4'-ylamino)phenol 
• 129190-28-9 2,6-bis(dimethylaminomethyl)-4-(7'-trifluoromethylquinazolin-4'-ylamino)phenol 
• 129190-34-7 2,6-bis(N-butyl-N-methylaminomethyl)-4-(7'-trifluoromethylquinazolin-4'-ylamino)phenol 
• 129210-19-1 2,6-bis(pyrrolidin-1'-ylmethyl)-4-(7''-trifluoromethylquinazolin-4''-ylamino)phenol 
• 129190-30-3 2,6-bis(dipropylaminomethyl)-4-(7'-trifluoromethylquinazolin-4'-ylamino)phenol 
• 129190-35-8 2,6-bis(piperidin-1'-ylmethyl)-4-(7''-trifluoromethylquinazolin-4''-ylamino)phenol 
• 129190-36-9 2,6-bis(3'-methylpiperidin-1'-ylmethyl)-4-(7''-trifluoromethylquinazolin-4''-ylamino)phenol 
• 129190-37-0 2,6-bis(4'-methylpiperidin-1'-ylmethyl)-4-(7''-trifluoromethylquinazolin-4''-ylamino)phenol 
• 129190-38-1 2,6-bis(3',5'-dimethylpiperidin-1'-ylmethyl)-4-(7''-trifluoromethylquinazolin-4''-ylamino)phenol 
• 129190-32-5 2,6-bis(dipentylaminomethyl)-4-(7'-trifluoromethylquinazolin-4'-ylamino)phenol 
• 129190-40-5 2,6-bis(4'-benzylpiperidin-1'-ylmethyl)-4-(7''-trifluoromethylquinazolin-4''-ylamino)phenol 
• 130806-70-1 3-(t-butylaminomethyl)-4'-chloro-5-(7''-trifluoromethylquinazolin-4''-ylamino)biphenyl-2-ol 
• 130806-69-8 4'-chloro-3-diethylaminomethyl-5-(7''-trifluoromethylquinqzolin-4''-ylamino)biphenyl-2-ol 
• 130806-71-2 4'-chloro-3-(pyrrolidin-1''-ylmethyl)-5-(7''-trifluoromethylquinazolin-4''-ylamino)biphenyl-2-ol 

Relevant academic research and scientific papers

Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors

In an effort to develop new cancer therapeutics, we have reported clinical candidate BPR1K871 (1) as a potent anticancer compound in MOLM-13 and MV4-11 leukemia models, as well as in colorectal and pancreatic animal models. As BPR1K871 lacks oral bioavailability, we continued searching for orally bioavailable analogs through drug-like property optimization. We optimized both the physicochemical properties (PCP) as well as in vitro rat liver microsomal stability of 1, with concomitant monitoring of aurora kinase enzyme inhibition as well as cellular anti-proliferative activity in HCT-116 cell line. Structural modification at the 6- and 7-position of quinazoline core of 1 led to the identification of 34 as an orally bioavailable (F% = 54) multi-kinase inhibitor, which exhibits potent anti-proliferative activity against various cancer cell lines. Quinazoline 34 is selected as a promising oral lead candidate for further preclinical evaluation.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Potential Antimalarials. IX Di-Mannich Bases of 4-(7'-Trifluoromethylquinazolin-4'-ylamino)phenol and 4-(7'-Trifluoromethylquinolin-4'-ylamino)phenol

Syntheses are reported for a series of di-Mannich bases of 4-(7'-trifluoromethylquinazolin-4'-ylamino)phenol derived from 4-chloro-7-trifluoromethylquinazoline with the di-Mannich bases of 4-aminophenol.Some analogous quinolines were prepared similarly.When tested for antimalarial activity against Plasmodium falciparum in vitro, the quinazolines were rather less active than the corresponding quinolines.